Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the Projected CAGR for the Diagnostic Biomarkers Market Size from 2025 to 2034?

The size of the diagnostic biomarkers market has seen significant expansion in the past few years. It’s forecasted that this market will rise from $65.25 billion in 2024 to reach $75.67 billion in 2025, representing a compound annual growth rate (CAGR) of 16.0%. The rate of growth in the past period can be linked to factors such as the increasing occurrence of chronic illnesses, advancements in the field of omics technologies, the growing need for personalized medicine, heightened awareness of the benefits of early disease detection, and an increase in the use of non-invasive diagnostic procedures.

The market for diagnostic biomarkers is projected to experience swift expansion in the coming years, escalating to $136.57 billion by 2029 with a compound annual growth rate (CAGR) of 15.9%. This upward trend during the forecast period is primarily due to the rising adoption of liquid biopsy procedures, an escalation in biomarker research funding, an increased concentration on precision medicine, and the widening use in neurodegenerative conditions. The forecast period is also set to witness key advancements such as the progression in artificial intelligence and machine learning, the fusion of multi-omics methodologies, the creation of point-of-care diagnostic instruments, a transition towards digital biomarkers, a surging usage of wearable health tracking devices, and a heightened focus on the validation and standardization of biomarkers.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21171&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Diagnostic Biomarkers Market?

The diagnostic biomarkers market is expanding due to the rising incidence of cancer. Factors such as changes in lifestyle, aging demographics, environmental exposure, and advancements in diagnostic methods contribute to this rising occurrence of cancer. Diagnostic biomarkers are essential in battling cancer as they facilitate early detection, accurate diagnosis, and personalized treatments, consequently enhancing patient outcomes. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the US, reported that cancer cases rose to 2,001,140 in January 2024 from 1,958,310 in 2023, an increase of 2.19%. Therefore, this rise in cancer prevalence propels the growth of the diagnostic biomarkers market.

What Segment Types Define the Diagnostic Biomarkers Market Structure?

The diagnostic biomarkers market covered in this report is segmented –

1) By Product: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers

2) By Application: Oncology, Metabolic Disease, Neurological Disease

3) By End User: Hospitals, Cancer Research Institutes, Diagnostic Labs

Subsegments:

1) By Safety Biomarkers: Toxicity Biomarkers, Organ-Specific Safety Biomarkers, Drug-Induced Injury Biomarkers

2) By Efficacy Biomarkers: Predictive Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers

3) By Validation Biomarkers: Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21171&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Diagnostic Biomarkers Market?

North America was the largest region in the diagnostic biomarkers market in 2024. The regions covered in the diagnostic biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Diagnostic Biomarkers Market?

Prominent entities in the diagnostic biomarkers market are prioritizing the development of non-invasive testing techniques, such as blood-based biomarker examinations, in a bid to increase patient comfort and improve accessibility to individualized treatment plans. Blood-based biomarker tests are diagnostic tools that evaluate specific biological indicators in the blood to identify or track diseases like Alzheimer’s in a less invasive manner. For example, in July 2023, Quanterix Corporation, an American life sciences firm, unveiled LucentAD, a blood-based biomarker exam explicitly designed to help healthcare professionals diagnose Alzheimer’s disease in patients with early cognitive symptoms. This test examines plasma levels of phosphorylated tau protein at the 181 residue (p-Tau 181), a biomarker linked with amyloid pathology in the brain, an essential sign of Alzheimer’s. LucentAD’s goal is to simplify the assessment procedure for possible Alzheimer’s patients by offering a diagnostic method that is less invasive and more accessible than traditional techniques such as cerebrospinal fluid analysis or amyloid positron emission tomography.

View the full report here:

https://www.thebusinessresearchcompany.com/report/diagnostic-biomarkers-global-market-report

What Is the Definition of the Diagnostic Biomarkers Market?

A diagnostic biomarker is a biological measure that assists in the diagnosis of a disease, helping to differentiate it from other conditions. It can encompass various findings, including laboratory results, radiological images, genetic markers, and physiological changes, and may also provide insights into disease progression and treatment efficacy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21171

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model